Recent Updates
Recently added Catalysts

Defactinib

Phase 2

Pancreas Cancer | Small molecule | Oncology |Verastem, Inc.|Last Updated: May 8, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment42
FDA Designations
No designations recorded
Clinical trial landscape

Defactinib · 8 trials · 14 indications

Phase 2 3Phase 1 5
NCT07126158Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaPancreatic Adenocarcinoma
RECRUITING36 Analytics
NCT04331041Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaPancreas Cancer
ACTIVE NOT_RECRUITING42 Analytics
NCT01951690Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerNon Small Cell Lung Cancer
COMPLETED55 Analytics
PHASE2RECRUITING
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Pancreatic AdenocarcinomaUnlock trial analytics
PHASE2ACTIVE NOT_RECRUITING
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Pancreas CancerUnlock trial analytics
PHASE2COMPLETED
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Non Small Cell Lung CancerUnlock trial analytics
Study Endpoints
Primary Endpoints
Progression-free survival (PFS) - Experimental Arm Only
Through completion of follow-up (up to 2 years)

Defined as the days from the date of standard of care (SOC) chemotherapy treatment start to progression or death.

Progression-free survival (PFS) (Experimental Arm only)
After completion of treatment (estimated to be 12 months)

* PFS is defined as the duration of time from start of standard of care chemotherapy treatment to time of progression or death, whichever occurs first. The alive patients without progression will be censored at the last follow-up. * Progressive disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

Demonstrate that VS-6063 (defactinib), will improve PFS at 12 weeks (PFS12) within each cohort.
From baseline through 12 weeks of treatment
Recommended phase II dose
Completion of the first cycle of all patients enrolled (approximately 25 months)

* The recommended phase II dose will be determined from the maximum tolerated dose (MTD) found in the dose escalation cohort. * The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity during the first cycle (21 days). Dose escalations will proceed until the MTD has been reached or the completion of cycle 5.

Response rate defined as Partial Response (PR) + Complete Response (CR) using Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria of all measurable target lesions present at the time of enrollment on trial.
6 months

For Cohort A, the primary objective will be to evaluate preliminary response rate of defactinib and avutometinib in patients with RAS mutant, BRAF mutant, NF1 mutant, and triple RAS/BRAF/NF1 wild type (wt) melanoma (includes RAF fusions). Measurable target lesions to be defined as all untreated and measurable (≥ 0.5 cm by 2 dimensional diameter measurements) present at the time of enrollment on study.

Frequency of dose limiting toxicities (DLTs).The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.
4 weeks

For Cohort B, a Phase 1 run-in will be performed with the primary objective of evaluating the safety and tolerability of the combination of defactinib, avutometinib, and encorafenib in patients with BRAF V600E/K mutant melanoma with at least one untreated brain metastasis.

Urine amount excreted (Ae)
Screening to 168h post-dose
Urine fraction of the dose excreted (Fe)
Screening to 168h post-dose
Urine cumulative amount excreted (Cum Ae)
Screening to 168h post-dose
Urine cumulative fraction of the dose excreted (Cum Fe)
Screening to 168h post-dose
Urine renal clearance (CLr)
Screening to 168h post-dose
Faeces Ae
Screening to 168h post-dose
Faeces Fe
Screening to 168h post-dose
Faeces Cum Ae
Screening to 168h post-dose
Faeces Cum Fe
Screening to 168h post-dose
All excreta Ae
Screening to 168h post-dose
All excreta Fe
Screening to 168h post-dose
All excreta Cum Ae
Screening to 168h post-dose
All excreta Cum Fe
Screening to 168h post-dose
All excreta non-renal clearance (CLnr)
Screening to 168h post-dose
Assess the Safety and Tolerability of Defactinib (VS-6063) in Japanese Subjects With Non-hematologic Malignancies
From start of treatment to end of treatment, an expected average of 12 weeks

A composite by dose level to include incidence of AEs, SAEs, dose interruptions and dose reductions as a measure of safety and tolerability. Abnormal Clinical significant laboratory results, ECG measurements, vital signs measurement, physical examination findings, and ECOG performance status were captured as adverse events. The severity of AEs were evaluated according to CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03

Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects)during the study (safety and tolerability).
From start of treatment to end of treatment, an expected average of 12 weeks

Adverse events and their frequency, duration and severity, as determined based on CTCAE 4.03

Determine the recommended phase 2 dose (RP2D) based on a combination of maximum tolerated dosed (MTD), review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study.
From start of treatment to end of cycle 1 (4 week cycles)

The RP2D will be determined based on the maximum tolerated dose (MTD) of defactinib (VS-6063) in combination with paclitaxel as determined by number of participants with dose limiting toxicities (DLTs) related to defactinib in combination with paclitaxel

Secondary Endpoints
Number of patients with acute toxicity - Experimental Arm Only
From start of treatment through 90 days
Number of patients with late toxicity - Experimental Arm Only
From day 91 through 2 years
Local control - Experimental Arm Only
At 12 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Experimental Arm: SBRT + Defactinib + AvutometinibEXPERIMENTALParticipants will receive approximately 12 months of treatment on study with 5 fractions of adaptive SBRT with 12 cycles of oral defactinib + avutometinib beginning on Day 2 of radiation. Cycles are 28 days in length. Defactinib is dosed twice a day and avutometinib is dosed twice a week (e.g. Monday and Thursday, Tuesday and Friday, etc.) on a 3 weeks on, 1 week off schedule. The first 6 participants will be enrolled in the Safety Lead-In cohort to monitor for dose-limiting toxicities. Patients who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 2 weeks). These patients will discontinue defactinib and avutometinib the day prior to the operation and will resume taking it 4 to 6 weeks after surgery for the remainder of the 12 cycles. Patients who are not candidates for surgical resection will continue to receive defactinib plus avutometinib uninterrupted.
Control Arm: SBRTACTIVE_COMPARATORParticipants will receive 5 fractions of adaptive SBRT.
Adaptive SBRT + DefactinibEXPERIMENTAL* Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation). * Participants who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 1 week). These participants will discontinue defactinib the day prior to the operation and will resume taking it for the remainder of the 17 cycles 4 to 6 weeks after surgery. Participants who are not candidates for surgical resection will continue to receive defactinib uninterrupted. All participants should receive 17 cycles of defactinib unless they experience disease progression or intolerable toxicity.
Adaptive SBRTACTIVE_COMPARATOR-Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT)
VS-6063 (defactinib)EXPERIMENTALAdministered orally BID in a 21 day cycle
Dose escalation (defactinib, pembrolizumab, gemcitabine)EXPERIMENTAL* Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle. * Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle. * Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle. * Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine.
Dose expansion (defactinib, pembrolizumab, gemcitabine)EXPERIMENTAL* Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle. * Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle. * Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle. * Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine.
Phase II, Defactinib and Avutometinib (Cohort A)EXPERIMENTALAvutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle. Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle.
Phase Ib, Defactinib, Avutometinib, and Encorafenib (Cohort B)EXPERIMENTALAvutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle. Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle. Encorafenib will be administered orally to a small cohort to a limited dose finding cohort using a Bayesian optimal interval (BOIN) design to evaluate safety, toxicity, and recommended phase II dose for dosage of encorafenib when combined with avutometinib and defactinib. Dose escalation/de-escalation levels for Encorafenib: Dose Level -1: 225 mg Daily (three 75mg capsules) Dose Level 0: 300 mg Daily (four 75mg capsules) Dose Level 1: 450 mg Daily (six 75mg capsules)
Phase II, Defactinib, Avutometinib, and Encorafenib (Cohort B)EXPERIMENTALAvutometinib will be administered at 3.2 mg biweekly orally (e.g., Monday/Thursday, Tuesday/Friday, or Wednesday/Saturday) for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle. Defactinib will be administered at 200 mg twice a day orally for 3 weeks, followed by a 1-week rest period, in each 4-week (28-day) cycle. Encorafinib will be administered orally at doses defined in the dose finding portion (225mg - 450mg) Daily continuously (days 1-28 of a 28 day cycle) for Cohort B.
Defactinib treatmentEXPERIMENTALSingle dose of 400 mg \[14C\]-defactinib, oral suspension
DefactinibEXPERIMENTALOral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
defactinib (VS-6063) plus paclitaxelEXPERIMENTALOral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
Interventions
NameTypeDescription
Stereotactic body radiotherapyRADIATIONMRIdian and Ethos (adaptive radiation platforms)
DefactinibDRUGTaken with 30 minutes of a meal
AvutometinibDRUGCan be taken without regard to food.
Adaptive stereotactic body radiation therapyDEVICE* Will be administered using MRIdian and Ethos * 50 Gy in 5 fractions
Tumor biopsyPROCEDURE-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
Research blood drawPROCEDURE-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
defactinib (VS-6063)DRUG -
PembrolizumabBIOLOGICAL -
GemcitabineDRUG -
EncorafenibDRUGEncorafinib administered orally per arm description.
PaclitaxelDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is considered borderline resectable or locally advanced per institutional standardized criteria of unresectability or medical inoperability (NCCN guidelines 2.2021 PANC-C 1 of 2). * Patients with...

Countries:United StatesJapan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06194929primaryCompletionDate: changed
LOWMay 26, 2026NCT07126158Status: NOT_YET_RECRUITING → RECRUITING
LOWMay 26, 2026NCT04331041primaryCompletionDate: changed
LOWMay 24, 2026NCT06194929studyFirstPostDate: changed
LOWMay 24, 2026NCT07126158studyFirstPostDate: changed
LOWMay 24, 2026NCT04331041studyFirstPostDate: changed